Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | PARG | Q86W56 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25191291 | 0.83 | HDAC4 (0.38) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL23540748 | 0.80 | KMT2A (0.43) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1941686 | 0.78 | KMT2A (0.51) | MEN1KMT2AALDH1A1SMN1; SMN2NPBWR1 | |
| SCHEMBL26970922 | 0.78 | LMNA (0.44) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL11971278 | 0.78 | GAA (0.35) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL27246864 | 0.75 | EDNRB (0.39) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL16830284 | 0.75 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL3772018 | 0.74 | SMN1; SMN2 (0.42) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22575360 | 0.73 | NAMPT (0.48) | ALDH1A1CA12CA1CA9STAT3 | |
| SCHEMBL14213987 | 0.72 | CA12 (0.38) | MEN1KMT2AALDH1A1MAPTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-9695154-B2 | Heteroaryl inhibitors of sumo activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160355504-A1 | HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | US | disclosed |
| WO-2015002994-A2 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | MEN1 4224/4885KMT2A 653/4885ALDH1A1 600/4885 |
| US-20160355504-A1 | HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO2, SUMO1 | MEN1 4646/4885KMT2A 888/4885ALDH1A1 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.